Combination of the EP and Anti-PD-1 Pathway or Anti-CTLA-4 for the Phase III Trial of Small-Cell Lung Cancer: A Meta-Analysis

The morbidity and mortality of lung cancer remain one of the highest among multiple cancers, respectively. Small-Cell Lung Cancer (SCLC) accounts for around 10%–15% of all lung cancers. Approximately two-thirds of the diagnosed SCLCs are in extensive stage (ES). Decades later, we still rely on the s...

Descripción completa

Detalles Bibliográficos
Autores principales: Abunasser, Abdulhakim A. A., Xue, Jinmin, Balawi, Ehab J. A., Zhu, Yuxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166470/
https://www.ncbi.nlm.nih.gov/pubmed/34122547
http://dx.doi.org/10.1155/2021/6662344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166470/
https://www.ncbi.nlm.nih.gov/pubmed/34122547
http://dx.doi.org/10.1155/2021/6662344

Ejemplares similares